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Introduction 
N6-(Δ2-Isopentenyl)adenosine (1, IPA), a modified 
nucleoside, is the only known cytokinin existing in 
animal cells. IPA has been detected in the cytosol of 
many eukaryotic and prokaryotic cells as a free 
compound or bound to tRNA. At the moment, however, 
the biological role of IPA in mammalians cells and its 
mechanism of action are not fully understood [1-3]. 
Spinola et al. [4] have recently demonstrated that IPA 
exerts a potent in vitro antitumoral activity on human epithelial cancer cell lines 
but has slight effect on tumor growth in rodents. This lack of in vivo activity could 
be related to the short plasma half-life of IPA, as for other nucleosides.  
 
Aim of the project/Experimental approach 
In order to identify compounds endowed with in vitro and in vivo antiproliferative 
activity, we investigated structural modifications of IPA. 
In the first year of our PhD project, we demonstrated that 
a minor modification of IPA side chain (i.e. hydrogenation 
of the double bond) yielded a compound showing only 
50% inhibition of cell growth and clone formation. 
Acyclonucleoside analogues of IPA were inactive. In the 
second year, we synthesized the O-isopentenylinosine (2) 
by reaction with 3,3-dimethylallyl bromide to investigate 
the effects of the change of the base on the antitumoral activity. We then 
synthesized deoxy-nucleosides derivatives (7-10) in order to study the importance 
of each hydroxyl group of the furanosidic moiety for the activity of IPA. For this 
purpose, only 2’-deoxyadenosine (3) was commercially available, so we 
synthesized the 3’-deoxy, 5’-
deoxy and 2’,3’-dideoxy 
adenosine (compounds 4, 5 e 6). 
Compounds 7-10 were obtained 
in satisfactory yield by reaction 
of nucleosides 3-6 with 3,3-
dimethylallyl bromide. All 
synthesized isopentenyl 
adenosine analogues 
(compounds 2, 7-10) have been 
tested in biological systems in 
vitro. Proliferation, clonogenity 
and migration assays were 
performed on the human 
N
NN
N
HN
O
OHOH
HO
1, IPA
N
NN
N
O
O
OHOH
HO
2
N
NN
N
HN
O
R1R2
R3
N
NN
N
NH2
O
R1R2
R3
3 : R1=H R2=R3=OH
4 : R2=H R1=R3=OH
5 : R3=H R1=R2=OH
6 : R1=R2=H R3=OH
7 : R1=H R2=R3=OH
8 : R2=H R1=R3=OH
9 : R3=H R1=R2=OH
10 : R1=R2=H R3=OH
neoplastic cell line T24 (bladder carcinoma) on proliferating and quiescent cell 
cultures (10 μM). These preliminary experiments showed that all molecules were 
not active on proliferating cells, confirming that for the antitumoral activity of IPA 
the ribose moiety has to be kept intact. 
 An interesting observation is related to the activity of compound 9 that was the 
only analogue of IPA that was able to cause cell death of quiescent cultures. In 
order to verify that 3’-deoxyisopentenyladenosine (9) has effect on different types 
of cell line we also tested 9 on proliferating and quiescent cell cultures (10 μM) of 
different human and murine carcinoma cell lines colon (caco2), bladder (J82), 
breast (MDAMB231) and rodent lung carcinoma (LLC). These trials indicated that 
the activity of compound 9 is comparable in all cell lines. 
Differently from compound 9, 3’-deoxyadenosine (5) was found to be inactive with 
quiescent cells and this result demonstrates the primary importance of the 
isopentenyl chain for the activity of compound 9. Additional studies are required 
in order to clarify the biological significance of  the selective activity of 9 on 
quiescent neoplastic cells. 
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